B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
Study Details
Study Description
Brief Summary
It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non Hodgkin's lymphoma. It will also explore the PK/PD manner and ORR in this study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
Phase I dose escalation study
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: B001,B001 dose escalation 5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg |
Biological: B001
4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
|
Outcome Measures
Primary Outcome Measures
- Safety of B001 as assessed by adverse reactions and events [42 days]
Incidence and intensity of adverse events according to NCI CTCAE 4.03 associated with increasing doses of B001
Secondary Outcome Measures
- Concentration-time curve of B001 [112 days]
Measure the concentration of B001 in serum at different time point to get a concentration-time curve.
- PD results of B001 [112 days]
Measure the number of CD19 positive B cell in peripheral blood
- Immunogenicity of B001 [112 days]
Content analysis of anti-B001 antibody
- ORR of B001 [112 days]
Objective response rate according to Response Criteria for Lymphoma(not including PET)and CLL Response Criteria
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age of 18-75, male or female.
-
Patients with the following histologically-documented hematologic malignancy: CD20 positive B-cell non Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to 2016 WHO Classification of Lymphoma.
-
Patients with relapsed/refractory CD20 positive B cell NHL (including CLL/SLL )
-
Life expectancy of at least 6 months.
-
ECOG-PS score of 0-1.
-
For patients of reproductive potential, pregnancy test should be negative 7 days before treatment , and use of a reliable means of contraception during the study and 12months after discontinuing treatment. Males should be willing to use barrier contraception during the study and 12months after discontinuing treatment.
-
Provision of signed and dated ,written informed consent prior to any study specific procedures, sampling and analyses.
Exclusion Criteria:
- Serious blood, renal or hepatic function impairment:
-
Absolute neutrophil count(ANC)<1.0*10^9/L(Except for those with bone marrow invasion)
-
Lymphocyte Count(LYM)>50*10^9/L
-
Haemoglobin(Hb)<70g/L(Except for those with bone marrow invasion)
-
Platelet count(PLT)<50*10^9/L(Except for those with bone marrow invasion)
-
Creatinine (Cr)>1.5xULN
-
Alanine transaminase (ALT)or Aspartate aminotransferase(AST)>2.5xULN
-
Total bilirubin (TBIL)>2xULN
-
Patients with any anti-tumor treatment (including steroid treatment) within 4 weeks or with any chronic unresolved toxicities from prior therapy greater than Grade 2 according to NCI-CTCAE 4.03.
-
Rituximab or any other anti-CD20 monoclonal antibody treatment within 3 weeks.
-
received blood transfusion and hemopoietic stimulating factor,eg. colony-stimulating factor (CSF)、Erythropoietin(EPO) within 2 weeks.
-
Radiotherapy within 3 months.
-
Major surgery within 28 days
-
History of tumor vaccine treatment.
-
Live-virus (live attenuated) vaccine treatment within 28 days
-
High dose of steroid treatment (hydroprednisone >10mg/day or relevant dose of other drugs)
-
Patients with history of hematopoietic stem cell transplantation or planning to receive hematopoietic stem cell transplantation within 3 months.
-
Patients with history of Gastrointestinal perforation and/or fistula within 6 months.
-
Lymphoma in CNS, ADIS related lymphoma
-
Active infection by bacteria,virus,fungus which required hospitalization or severe infection required intravenous administration of antibiotics
-
Concomitant severe disease including but not limited to:
-
Known HIV or ADIS related disease
-
Asthma or interstitial lung disease or severe COPD
-
Myocardial infarction, unstable angina, Cardiovascular interventional surgery, Congestive heart failure(CHF; NYHA Grade II-IV), symptomatic or poorly controlled arrhythmia within 6 months before enrolling
-
The systolic pressure ≥140mmHg,or diastolic pressure≥90mmHg post treatment.
-
Acute or chronic hypotension(<90/60mmHg)
-
History of toxic epidermal necrolysis or Stevens-Johnson syndrome
-
Rheumatoid arthritis Granulomatous angiitis or microscopic polyangiitis
-
Ileus or history of following disease: inflammatory bowel disease or extensive intestinal resection(extensive bowel resection or hemicolectomy, combining chronic diarrhea), Crohn's disease, ulcerative colitis or chronic diarrhea.
-
Previous or concomitant malignant, except basal-cell carcinoma or squamous cell carcinoma and/or cervical carcinoma in situ or effectively treated hematological malignancy and solid tumor that has been remission for more than 3 years and is considered to be cured.
-
Any history may affect the study result: increasing dosing risk or affect lab values and Judgment by the investigator that the patient should not participate in the study,
-
HBsAg positive; HBcAb positive and HBV-DNA≥upper limit of detection, HCV positive; HIV positive
-
Allergy to humanized antibody or human-mouse chimeric antibody.
-
Woman who are breast feeding or pregnant
-
Judgment by the investigator that the patient should not participate in the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The second affiliated hospital of Guangzhou medical university | Guangzhou | Guangdong | China | |
2 | Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Tianjin | Tianjin | China | 300020 |
Sponsors and Collaborators
- Shanghai Pharmaceuticals Holding Co., Ltd
Investigators
- Principal Investigator: Lugui Qiu, Doctor, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Principal Investigator: Junyuan Qi, Doctor, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B001-101